Clinical

ALPHARETTA, Ga., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced…

VANCOUVER, British Columbia, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Blender Bites Limited. (the “Company”, “Blender Bites” or “Blender”), (CSE: BITE, FWB: JL4, WKN: A3DMEJ), is excited to announce it has entered into a share purchase…

Pune, India, Oct. 27, 2023 (GLOBE NEWSWIRE) -- A clinical data management tool is employed in clinical research to manage a clinical trial's data. Clinical data management is an initial phase in clinical research, leading to generating…

New York, USA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nasopharyngeal Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 28+ Companies Working in the Domain The prevalence of…

Dose response demonstrated in favor of highest tested dose of 3E10 vg/eye, including 100% reduction in supplemental anti-VEGF injections (4 of 4 evaluable patients injection-free) and a clinically meaningful reduction in mean central…

More often, people are turning to consumer wearable devices, such as smartwatches, to monitor their health and physical activity. Using these wearable devices, a study led by Michigan Medicine and the University of Missouri with Saint…

Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”),  a clinical stage biopharmaceutical company developing a pipeline of products aimed at…

Although bones have the ability to regenerate and repair themselves, they are generally unable to do so when the injury is larger than a small break or chip. In a study just published in Inflammation and Regeneration, Japanese researchers…

HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts…

Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage…